Novel γ-secretase modulators: A review of patents from 2008 to 2010

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 2, 2011, Pages 205-226

  Pettersson, Martin ^a   Kauffman, Gregory W ^a   Am Ende, Christopher W ^a   Patel, Nandini C ^a   Stiff, Cory ^a   Tran, Tuan P ^a   Johnson, Douglas S ^a  

^a PFIZER INC   (United States)

Author keywords

secretase; A 42; Alzheimer's disease; APP; modulator; Notch

Indexed keywords

ALKENE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; FLURBIPROFEN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; NEUROTOXIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLACETIC ACID DERIVATIVE; SEMAGACESTAT;

ALZHEIMER DISEASE; DRUG IDENTIFICATION; DRUG STRUCTURE; HUMAN; NEUROTOXICITY; NONHUMAN; REVIEW;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; PATENTS AS TOPIC; PROTEASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79952904028     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.547479     Document Type: Review

References (130)

1. Bergmans BA, De Strooper B. gamma-Secretases: From cell biology to therapeutic strategies. Lancet Neurol 2010;9:215-26
2. Selkoe DJ, Wolfe MS. Presenilin: Running with scissors in the membrane. Cell 2007;131:215-21 (Pubitemid 47576152)
3. Wolfe MS. The gamma-secretase complex: Membrane-embedded proteolytic ensemble. Biochemistry 2006;45:7931-9 (Pubitemid 43993216)
4. Ahn K, Shelton CC, Tian Y, et al Activation and intrinsic gamma-secretase activity of presenilin 1. Proc Natl Acad Sci USA 2010 doi: 10.1073/pnas. 1013246107
5. Li YM, Xu M, Lai MT, et al Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1. Nature 2000;405:689-94 (Pubitemid 30428655)
6. Esler WP, Kimberly WT, Ostaszewski BL, et al Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1. Nat Cell Biol 2000;2:428-34
7. Beel AJ, Sanders CR. Substrate specificity of gamma-secretase and other intramembrane proteases. Cell Mol Life Sci 2008;65:1311-34
8. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 2002;297:353-6 (Pubitemid 34790756)
9. Tanzi RE, Bertram L. Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. Cell 2005;120:545-55 (Pubitemid 40269768)
10. Bertram L, Lill CM, Tanzi RE. The genetics of Alzheimer disease: Back to the future. Neuron 2010;68:270-81
11. Fleisher AS, Raman R, Siemers ER, et al Phase 2 safety trial targeting amyloid beta production with a gamma-secretase inhibitor in Alzheimer disease. Arch Neurol 2008;65:1031-8
12. Bateman RJ, Siemers ER, Mawuenyega KG, et al A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol 2009;66:48-54
13. Extance A. Alzheimer's failure raises questions about disease-modifying strategies. Nat Rev Drug Discov 2010;9:749-51
14. De Strooper B, Annaert W, Cupers P, et al A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 1999;398:518-22
15. Wong GT, Manfra D, Poulet FM, et al Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem 2004;279:12876-82
16. van Es JH, van Gijn ME, Riccio O, et al Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005;435:959-63 (Pubitemid 40896322)
17. Costa RM, Drew C, Silva AJ. Notch to remember. Trends Neurosci 2005;28:429-35 (Pubitemid 40982556)
18. Louvi A, Artavanis-Tsakonas S. Notch signalling in vertebrate neural development. Nat Rev Neurosci 2006;7:93-102 (Pubitemid 43151596)
19. Gillman KW, Starrett JE, Parker MF, et al Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable gamma-secretase inhibitor. ACS Med Chem Lett 2010;1:120-4
20. Kreft AF, Martone R, Porte A. Recent advances in the identification of gamma-secretase inhibitors to clinically test the Abeta oligomer hypothesis of Alzheimer's disease. J Med Chem 2009;52:6169-88
21. Weggen S, Eriksen JL, Das P, et al A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature 2001;414:212-16 (Pubitemid 33051236)
22. Eriksen JL, Sagi SA, Smith TE, et al NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin Invest 2003;112:440-9 (Pubitemid 38063773)
23. Weggen S, Eriksen JL, Sagi SA, et al Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid beta 42 production by direct modulation of gamma-secretase activity. J Biol Chem 2003;278:31831-7 (Pubitemid 37048365)
24. Peretto I, Radaelli S, Parini C, et al Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1-42) secretion. J Med Chem 2005;48:5705-20 (Pubitemid 41298345)
25. Wilcock GK, Black SE, Hendrix SB, et al Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: A randomised phase II trial. Lancet Neurol 2008;7:483-93
26. Imbimbo BP. Why did tarenflurbil fail in Alzheimer's disease? J Alzheimers Dis 2009;17:757-60
27. Imbimbo BP, Del Giudice E, Colavito D, et al 1-(3',4'-Dichloro-2- fluoro[1,1'-biphenyl]-4-yl)- cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity. J Pharmacol Exp Ther 2007;323:822-30 (Pubitemid 350146064)
28. Safety, pharmacokinetics and pharmacodynamics study of treatment with CHF5074 in healthy young male subjects. Available from: Www.clinicaltrials.gov/ ct2/show/ NCT00954252?term=CHF5074&rank=2 [Last accessed 29 October 2010]
29. Takahashi Y, Hayashi I, Tominari Y, et al Sulindac sulfide is a noncompetitive gamma-secretase inhibitor that preferentially reduces Abeta 42 generation. J Biol Chem 2003;278:18664-70 (Pubitemid 36799494)
30. Beher D, Clarke EE, Wrigley JD, et al Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J Biol Chem 2004;279:43419-26 (Pubitemid 39390641)
31. Zettl H, Weggen S, Schneider P, et al Exploring the chemical space of gamma-secretase modulators. Trends Pharmacol Sci 2010;31:402-10
32. Kukar TL, Ladd TB, Bann MA, et al Substrate-targeting gamma-secretase modulators. Nature 2008;453:925-9
33. Beel AJ, Barrett P, Schnier PD, et al Nonspecificity of binding of gamma-secretase modulators to the amyloid precursor protein. Biochemistry 2009;48:11837-9
34. Page RM, Gutsmiedl A, Fukumori A, et al Beta-amyloid precursor protein mutants respond to gamma-secretase modulators. J Biol Chem 2010;285:17798-810
35. Okochi M, Fukumori A, Jiang J, et al Secretion of the Notch-1 Abeta-like peptide during Notch signaling. J Biol Chem 2006;281:7890-8 (Pubitemid 43847405)
36. Richter L, Munter LM, Ness J, et al Amyloid beta 42 peptide-lowering compounds directly bind to Abeta and interfere with amyloid precursor protein (APP) transmembrane dimerization. Proc Natl Acad Sci USA 2010;107:14597-602
37. Lleo A, Berezovska O, Herl L, et al Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat Med 2004;10:1065-6 (Pubitemid 39424866)
38. Uemura K, Farner KC, Hashimoto T, et al Substrate docking to gamma-secretase allows access of gamma-secretase modulators to an allosteric site. Nat Commun 2010;1:130
39. Neurogenetics, Inc. WO04110350; 2004
40. Eisai Co., Ltd. WO05115990; 2005
41. Hashimoto T, Ishibashi A, Hagiwara H, et al E2012: A novel gamma-secretase modulator -pharmacology part [abstract P1-236]. 13th Int Conf Alzheimer's Dis Relat Disord (ICAD); 10 - 15 July 2010; Honolulu
42. Recruiting a randomized, double-blind, placebo-controlled, sequential ascending, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of E2212 in healthy subjects. Available from: Www. clinicaltrials.gov/ct2/results?term=E2212 [Last accessed 29 October 2010]
43. Portelius E, Van Broeck B, Andreasson U, et al Acute effect on the Abeta isoform pattern in CSF in response to gamma-secretase modulator and inhibitor treatment in dogs. J Alzheimers Dis 2010;21:1005-12
44. Kounnas MZ, Danks AM, Cheng S, et al Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease. Neuron 2010;67:769-80
45. Garofalo AW. Patents targeting gamma-secretase inhibition and modulation for the treatment of Alzheimer's disease: 2004-2008. Expert Opin Ther Pat 2008;18:693-703
46. Hattori K, Wakabayashi H, Tamaki K. Predicting key example compounds in competitors' patent applications using structural information alone. J Chem Inf Model 2008;48:135-42 (Pubitemid 351271058)
47. Myriad Genetics, Inc. US080249135; 2008
48. Merck & Co., Inc. WO08085301; 2008
49. Stanton MG, Hubbs J, Sloman D, et al Fluorinated piperidine acetic acids as gamma-secretase modulators. Bioorg Med Chem Lett 2010;20:755-8
50. Hall A, Elliott RL, Giblin GM, et al Piperidine-derived gamma-secretase modulators. Bioorg Med Chem Lett 2010;20:1306-11
51. EnVivo Pharmaceuticals, Inc. WO09036428; 2009
52. EnVivo Pharmaceuticals, Inc. WO09086277; 2009
53. Janssen Pharmaceutica, N.V. WO09051948; 2009
54. Janssen Pharmaceutica, N.V. WO09052079; 2009
55. Janssen Pharmaceutica, N.V. WO09052126; 2009
56. Janssen Pharmaceutica, N.V. WO09052334; 2009
57. Janssen Pharmaceutica, N.V. WO09052350; 2009
58. Janssen Pharmaceutica, N.V. WO10011626; 2010
59. Eisai Co., Ltd. US060004013; 2006
60. Eisai Co., Ltd. WO06046575; 2006
61. Eisai R&D Management Co., Ltd. WO07058305; 2007
62. Eisai R&D Management Co., Ltd. WO08140111; 2008
63. Eisai R&D Management Co., Ltd. WO07058304; 2007
64. Imbimbo BP. Alzheimer's disease: Gamma-secretase inhibitors. Drug Discov Today Ther Strateg 2008;5:169-75
65. Imbimbo BP. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr Top Med Chem 2008;8:54-61 (Pubitemid 351791047)
66. FY2009 Product Creation Meeting, 18 December 2009, Eisai Co., Ltd. Available from: Www.eisai.co.jp/pdf/ eir/emat/material20091218e.pdf, [Last accessed 23 October 2010]
67. Eisai R&D Management Co., Ltd. US070117839; 2007
68. Eisai R&D Management Co., Ltd. US070117798; 2007
69. Eisai R&D Management Co., Ltd. US080207900; 2008
70. Eisai R&D Management Co., Ltd. WO07102580; 2007
71. Eisai R&D Management Co., Ltd. WO09028588; 2009
72. Eisai R&D Management Co., Ltd. US090062529; 2009
73. Eisai R&D Management Co., Ltd. WO10025197; 2010
74. Eisai R&D Management Co., Ltd. WO10098496; 2010
75. Eisai R&D Management Co., Ltd. WO10098332; 2010
76. Eisai R&D Management Co., Ltd. WO10098490; 2010
77. Eisai R&D Management Co., Ltd. WO10098495; 2010
78. Calculated using clogP v4.3. (2008) BioByte Software, BioByte Corporation, Claremont, CA
79. Merck & Co., Inc. WO08097538; 2008
80. Schering Corp. WO09005729; 2009
81. Schering Corp. WO09045314; 2009
82. Schering Corp. WO09020580; 2009
83. Schering Corp. WO08153792; 2008
84. Schering Corp. WO08153793; 2008
85. Schering Corp. WO10054067; 2010
86. Schering Corp. WO08137139; 2008
87. Schering Corp. WO10054078; 2010
88. Schering Corp. WO10054064; 2010
89. Schering Corp. WO09061699; 2009
90. Caldwell JP, Bennett CE, McCracken TM, et al Iminoheterocycles as gamma-secretase modulators. Bioorg Med Chem Lett 2010;20:5380-4
91. Zhu Z, Sun ZY, Ye Y, et al Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I-inhibitor design and validation. J Med Chem 2010;53:951-65
92. Dosed orally at 10 mg/kg. Brain concentration at 6 h for 35 and 37 were 914 and 275 ng/g, respectively
93. Schering Corp. WO10075203; 2010
94. Schering Corp. WO10075204; 2010
95. Schering Corp. WO09108766; 2009
96. Schering Corp. WO09032277; 2009
97. Huang X, Aslanian R, Zhou W, et al The discovery of pyridone and pyridazone heterocycles as gamma-secretase modulators. ACS Med Chem Lett 2010;1:184-7
98. Schering Corp. WO09076337; 2009
99. Schering Corp. US100137320; 2010
100. Schering Corp. WO09076352; 2009
101. Schering Corp. WO09073779; 2009
102. Merck & Co., Inc. WO08156580; 2008
103. Merck & Co., Inc. WO10071741; 2010
104. Merck & Co., Inc. WO10077582; 2010
105. Eisai R&D Management Co., Ltd. WO10098488; 2010
106. Glaxo Group Ltd. WO09050227; 2009
107. Hoffmann-La Roche, Inc. US080280948; 2008
108. Hoffmann-La Roche, Inc. WO09087127; 2009
109. Hoffmann-La Roche, Inc. WO09103652; 2009
110. Hoffmann-La Roche, Inc. WO10040661; 2010
111. Hoffmann-La Roche, Inc. WO10052199; 2010
112. AstraZeneca AB. WO10053438; 2010
113. Ortho-McNeil-Janssen Pharmaceuticals, Inc. WO10070008; 2010
114. Ortho-McNeil-Janssen Pharmaceuticals, Inc. WO10089292; 2010
115. Ortho-McNeil-Janssen Pharmaceuticals, Inc. WO10094647; 2010
116. Bristol-Myers Squibb Co. WO10083141; 2010
117. Eisai R&D Management Co., Ltd. WO07135969; 2007
118. TorreyPines Therapeutics, Inc. WO08137102; 2008
119. Amgen, Inc. WO09137404; 2009
120. Amgen, Inc. WO09075874; 2009
121. Pfizer, Inc. WO10100606; 2010
122. Merck & Co., Inc. WO08100412; 2008
123. Merck & Co., Inc. WO08099210; 2008
124. Merck & Co., Inc. WO10019392; 2010
125. Merck & Co., Inc. WO10019393; 2010
126. Rivkin A, Ahearn SP, Chichetti SM, et al Piperazinyl pyrimidine derivatives as potent gamma-secretase modulators. Bioorg Med Chem Lett 2010;20:1269-71
127. Rivkin A, Ahearn SP, Chichetti SM, et al Purine derivatives as potent gamma-secretase modulators. Bioorg Med Chem Lett 2010;20:2279-82
128. Wager TT, Ramalakshmi YC, Hou X, et al Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. ACS Chem Neurosci 2010;1:420-35
129. Morphy R. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J Med Chem 2006;49:2969-78
130. Hughes JD, Blagg J, Price DA, et al Physiochemical drug properties associated with in vivo toxicological outcomes. Bioorg Med Chem Lett 2008;18:4872-5